Tag: Parkinson’s

Intec Pharma’s Parkinson’s Treatment Failed in Comparison Trial

clinical-trial-material
Shares of Israel-based Intec Pharma Ltd. are down nearly 82% in premarket trading after the company announced its Phase III Parkinson’s disease therapy failed to demonstrate statistical superiority to...

Partnership for New Parkinson’s Disease Treatment

The University of Dundee‘s Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parki...

PhoreMost and C4X Discovery Partner in Neurodegeneration Focused Drug Discovery

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, and C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today an...

Hyundai Pharmaceutical Launched Korea’s First Parkinson’s Disease Treatment

korea
Hyundai Pharmaceutical announced on June 20 that it has launched Korea’s first Parkinson's disease treatment Ropinirole hydrochloride (HCl). The original product is global pharmaceutical company GS...

Ireland to Launch Research for Better Understanding of Parkinson’s

A new research study aims to deepen the understanding of Parkinson’s so that better treatments can be developed in the future. The project, which will be coordinated by RCSI, has been awarded €7m by t...

Servier and Oncodesign Team Up for R&D Parkinson’s Drug

Servier, an international pharmaceutical company governed by a non-profit foundation, and biopharmaceutical company, Oncodesign have announced a strategic partnership for the research and development ...

Zydus Cadila Announced First Approval for Transdermal Product in US

Zydus Cadila has received the approval from the USFDA to market Rivastigmine Transdermal System (US RLD – EXELON® PATCH), 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, marking its first approval fo...

FDA Rejected Sunovion’s Parkinson’s Drug

The U.S. Food and Drug Administration (FDA) rejected Sunovion Pharmaceuticals’ experimental treatment for OFF episodes of Parkinson’s disease. The regulatory agency issued a Complete Response Lette...

Generic for Alzheimer’s and Parkinson’s Approved by FDA

The U.S. Food and Drug Administration (FDA) approved Bridgewater, NJ-based Amneal Pharmaceuticals’ generic version of Novartis’ Exelon Patch (Rivastigmine Transdermal System) for dementia related to A...

Acorda’s Drug for Parkinson’s and OFF Episodes Approved by FDA

Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that the U.S. Food and Drug Administration approved INBRIJA™ for intermittent treatment of OFF episodes in people with Parkinson’s disease treated wit...